抗甲基乙二醛修饰载脂蛋白B100自身抗体与1型糖尿病冠状动脉粥样硬化和视网膜病变减少相关
本研究在1型糖尿病患者中检测抗甲基乙二醛(MGO)修饰载脂蛋白B100(apoB100)及其肽段5的IgM和IgG自身抗体,并评估其与冠状动脉粥样硬化和视网膜病变的关联。发现MGO-apoB100 IgM和MGO-p5 IgM水平较高者冠状动脉狭窄更轻,且在复制队列中验证;增殖性视网膜病变患者这些抗体水平显著低于背景性视网膜病变者。提示针对AGE修饰apoB100的自身抗体可能具有血管保护作用。
要点
- MGO-apoB100 IgM和MGO-p5 IgM水平较高与1型糖尿病患者冠状动脉狭窄程度较轻独立相关。
- 该 inverse 关联在复制队列中得到验证,支持结果的稳健性。
- 增殖性视网膜病变患者的MGO-apoB100 IgM和MGO-p5 IgM水平显著低于背景性视网膜病变者。
核心结论
- 抗AGE修饰apoB100的自身抗体与1型糖尿病患者的冠状动脉粥样硬化和增殖性视网膜病变呈负相关,提示这些自身抗体可能具有血管保护效应。
研究设计与样本
- 研究纳入Dialong研究中103例1型糖尿病患者和63例对照者,并在Oslo研究27例1型糖尿病患者中复制。
- 采用ELISA检测血浆中抗MGO-apoB100和MGO-p5的IgM和IgG抗体。
- 冠状动脉粥样硬化通过计算机断层扫描冠状动脉造影或血管内超声评估,视网膜病变通过视网膜照片分类。
主要发现
- 无冠状动脉狭窄的糖尿病患者MGO-apoB100 IgM中位水平为96.2 AU(IQR 71-126.8),显著高于显著狭窄者的54 AU(IQR 36.1-85.4),P=0.003。
- 无冠状动脉狭窄者MGO-p5 IgM中位水平为77.4 AU(IQR 58-106),显著高于显著狭窄者的36.9 AU(IQR 28.9-57.4),P=0.005。
- 校正混杂因素后,MGO-apoB100 IgM与较轻的冠状动脉狭窄相关,OR为0.2(95%CI 0.05-0.6),P=0.01;MGO-p5 IgM的OR为0.22(95%CI 0.06-0.75),P=0.02。
- MGO-p5 IgM与冠状动脉狭窄的负相关在复制队列中得到确认。
- 增殖性视网膜病变患者的MGO-apoB100 IgM和MGO-p5 IgM水平显著低于背景性视网膜病变患者。
临床怎么用
- 在1型糖尿病患者的风险评估中,可关注抗MGO-apoB100和MGO-p5 IgM抗体水平,但其常规临床应用尚需进一步研究。
- 这些自身抗体可能作为血管保护效应的生物标志物,未来或有助于识别冠状动脉粥样硬化和增殖性视网膜病变低风险患者。
局限性
- 研究为观察性设计,无法确定自身抗体与血管并发症之间的因果关系。
- 样本量有限(Dialong研究103例糖尿病患者,Oslo复制队列27例),结果需在更大规模队列中验证。
- 视网膜病变分类基于视网膜照片,冠状动脉评估方法在两组中可能不完全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Methylglyoxal (MGO), a reactive aldehyde forming advanced glycation end products (AGEs), is increased in diabetes and recognized by the immune system, resulting in anti-AGE-specific autoantibodies. The association of these immune responses with macro- and microvascular complications in type 1 diabetes remains unclarified. We investigated associations between MGO-modified apolipoprotein B100 (apoB100) and apoB100 peptide 5 (MGO-p5) autoantibodies and coronary atherosclerosis and retinopathy in type 1 diabetes. RESEARCH DESIGN AND METHODS: IgM and IgG against MGO-apoB100 and MGO-p5 were measured by ELISA in plasma from 103 subjects with type 1 diabetes and 63 control subjects (Dialong study) and in a replication cohort of 27 subjects with type 1 diabetes (Oslo study). Coronary atherosclerosis was assessed by computed tomography coronary angiography or intravascular ultrasound. Retinopathy was classified by retinal photos. RESULTS: MGO-apoB100 IgM and MGO-p5 IgM levels were higher in subjects with diabetes with no coronary artery stenosis compared with subjects with significant stenosis (median [interquartile range]: 96.2 arbitrary units [AU] [71-126.8] vs. 54 AU [36.1-85.4], P = 0.003 for MGO-apoB100; and 77.4 AU [58-106] vs. 36.9 AU [28.9-57.4], P = 0.005 for MGO-p5). MGO-apoB100 IgM and MGO-p5 IgM were associated with less severe coronary stenosis after adjusting for confounders (odds ratio 0.2 [95% CI 0.05-0.6], P = 0.01; and 0.22 [0.06-0.75], P = 0.02). The inverse association of MGO-p5 IgM and coronary stenosis was confirmed in the replication cohort. Subjects with proliferative retinopathy had significantly lower MGO-apoB100 IgM and MGO-p5 IgM than those with background retinopathy. CONCLUSIONS: Autoantibodies against AGE-modified apoB100 are inversely associated with coronary atherosclerosis and proliferative retinopathy, suggesting vascular protective effects of these autoantibodies in type 1 diabetes.
引用
- Sveen KA, Bech Holte K, Svanteson M, et al. Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes. Diabetes Care. 2021. PMID: 33858856. doi:10.2337/dc20-2089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。